Expert public only
It is our pleasure to cordially invite you again to the upcoming CCCC-/DKTK Workshop, which will focus on DNA repair mechanisms and present approaches to develop therapeutic and diagnostic applications.
CCCC-/DKTK WORKSHOP DNA Repair
Date: 25th November, 2016
Time: 14:30 – 17:00
Venue: Charité Comprehensive Cancer Center, Konferenzraum, level 3
Invalidenstr. 80 / Virchowweg 23, 10117 Berlin
Michela Di Virgilio, Max Delbrück Center for Molecular Medicine (MDC) focuses on "Regulation of DNA repair in Immunity and Cancer". The Di Virgilio group investigates the regulation of DNA double-strand break (DSB) repair in B lymphocytes in the context of both immunoglobulin Class Switch Recombination and DNA replication, with the purpose of understanding how deregulation of these processes predisposes to immunodeficiencies and carcinogenesis.
Cläre von Neubeck, DKTK Partner-site Dresden, University Cancer Center Dresden, OncoRay – National Center for Radiation Research in Oncology, summarizes the technical developments, ongoing work and necessary steps to develop a clinically relevant, predictive biomarker assay. : “The gammaH2AX assay - predicting radiation response based on DNA repair capacity”. Following radiation exposure, the phosphorylation of histone H2AX (gammaH2AX) is one of the early events in the DNA repair pathways for DNA double strand break repair. We could show that persisting (residual) gammaH2AX foci correlate with the local tumour control of xenografted human tumours in vivo and the slopes of the dose response curves of ex vivo irradiated tumour biopsies. This allows to distinguish between radio-sensitive and radio-resistant patient-derived tumour samples.
Ilja Demuth, Charité – Universitätsmedizin, Institute of Medical Genetics, focuses on “ The nuclease hSNM1B/Apollo functions in DNA-damage response and telomere maintenance”. The nuclease hSNM1B/Apollo is involved in the cellular response to DNA-damage induced by DNA interstrand crosslinking agents and ionizing radiation. The talk will focus on hSNM1B/Apollo’s putative role in the Fanconi Anemia/BRCA pathway.
Tanja Schwerdtle, University of Potsdam, Institute of Nutritional Science, gives an overview on “DNA repair in the field of toxicity testing”.
Ingeborg Tinhofer-Keilholz, Charité – Universitätsmedizin, Dept. of Radiooncology and Radiotherapy: “The potential of PARP inhibitors as radiosensitizing agents in head and neck cancer”. Current radiochemotherapy regimens for squamous cell carcinoma of the head and neck (SCCHN) are frequently not curative, necessitating novel therapeutic strategies. Inhibitors of poly(ADP-ribose) polymerases (PARPi), either alone or in combination with chemo- and radiotherapy have been shown to be highly active in tumor cells with intrinsic defects in DNA repair. In SCCHN, frequent occurrence of genomic alterations affecting the capacity of DNA repair has been reported. We have analysed the radiosensitizing activity of the PARP inhibitor olaparib in 10 cells line models of SCCHN. These studies revealed that combination of olaparib with irradiation is highly active in SCCHN cells, even in cell lines with p53 dysfunctions and primary resistance to irradiation / cisplatin. In the talk, our data and the results from other groups on the clinical potential of PARP inhibitors in SCCHN, possible biomarkers for patient selection and mechanisms of resistance will be discussed.
All are most warmly invited to attend.
Please feel free to circulate this invitation to colleagues who might be interested.
We look very much forward to an interesting exchange of thoughts and experience as well as to exciting discussions.
Ingeborg Tinhofer-Keilholz Ulrich Keilholz
Organizational and administrative matters
Charité – Universitätsmedizin Berlin
Michaela Di Virgillio
Max Delbrück Center for Molecular Medicine (MDC)
Cläre v. Neubeck
DKTK Partner-site Dresden, University Cancer Center Dresden, OncoRay – National Center for Radiation Research in Oncology
University of Potsdam, Institute of Nutritional Science
Charité – Universitätsmedizin Berlin
Deutsches Konsortium für Translationale Krebsforschung (DKTK), Standort Berlin und Charité Comprehensive Cancer Center (CCCC)
25th November, 2016
14:30 - 17:00
Charité Comprehensive Cancer Center
Konferenzraum, Level 3
Invalidenstr. 80 / Virchowweg 23